Pregnancy, the birth and the first months after, with type 1 in the room

The team that holds the work, named once

The operational anchor of a type 1 pregnancy is the joint antenatal-diabetes team. In most UK trusts the team includes the diabetes consultant, the diabetes specialist nurse, the obstetrician with an interest in diabetes, the midwife who runs the joint clinic, the dietitian, and the neonatology team for the third trimester and the delivery itself. The reader sees the team across the pregnancy in a pattern set at the booking visit; the visits are typically more frequent than in a non-diabetes pregnancy.

We hold the work alongside the team. The reader is the woman with type 1 making the decisions; the partner often carries the supporting work of the alerts on a second phone, the prescription pickup, the night-time hand on the shoulder. The team holds the operational pieces; the household holds the practical day-to-day; the reader holds the decision. None of the three is the back-up.

The pregnancy target range, named in numbers

The NICE guideline NG3 anchors the pregnancy glucose target range at 3.5 to 7.8 mmol/L (63 to 140 mg/dL) for most of the pregnancy. The range is tighter than the standard adult target range outside pregnancy; the tighter range is the published evidence base for the strongest neonatal outcomes. The range is a target, not a personal prescription; the joint antenatal-diabetes team reads the range alongside the reader’s own data and adjusts the operational targets for the reader’s personal picture.

The CONCEPTT trial (Feig 2017) showed that continuous glucose monitoring use in pregnancy improved neonatal outcomes in type 1 pregnancy compared with capillary monitoring alone in the trial cohort. CGM is now standard of care in type 1 pregnancy in most UK trusts; the CGM trace is the daily-data anchor the antenatal-diabetes team reads with the reader at every visit.

AHCL in pregnancy, the trial evidence and the device choice

The published evidence base for hybrid closed-loop and advanced hybrid closed-loop in type 1 pregnancy is now anchored in two randomised trials with overlapping findings. Both trials used pregnancy-specific target bands set by the antenatal-diabetes team; the device is not used in pregnancy with the same target settings as outside pregnancy. Both trials saw improvements in time-in-range without an increase in hypoglycaemia in the trial cohorts.

AiDAPT (Lee 2023; CamAPS FX, hybrid closed-loop). AiDAPT randomised women with type 1 pregnancy to CamAPS FX hybrid closed-loop or standard insulin delivery. The trial showed an improvement in time-in-range across the pregnancy with the hybrid closed-loop arm. CamAPS FX is the licensed hybrid closed-loop system for type 1 pregnancy in the UK as of the trial’s reporting; the system runs a pregnancy-specific target band set by the antenatal-diabetes team.

CRISTAL (Benhalima 2024; MiniMed 780G). CRISTAL randomised women with type 1 pregnancy to MiniMed 780G advanced hybrid closed-loop or standard insulin delivery. The trial added further evidence of AHCL benefit during pregnancy in type 1 diabetes. The 780G is used in pregnancy with a pregnancy-specific target band set by the antenatal-diabetes team; the band is tighter than the outside-pregnancy band.

The AID Optimiser is a Grade D educational synthesis on a Grade A and B evidence base, reviewed by manufacturer global medical leads at CamAPS, MiniMed, Tandem, and Insulet; it is never endorsed by, validated by, or co-developed with them. It is not a substitute for the conversation with your diabetes team. The Optimiser is not used for pregnancy-specific settings; those live with the antenatal-diabetes team and are set per trust protocol.

The device-choice conversation in pregnancy is one the antenatal-diabetes team holds with the reader. Some readers continue on the device they used pre-pregnancy with pregnancy-specific settings; some change device for the pregnancy on the team’s recommendation. Both routes are anchored in the trial evidence above; the choice is the team’s and the reader’s, made together.

Intrapartum and the first 24 to 72 hours after the birth

The intrapartum hours and the first 24 to 72 hours after the birth are the most operationally intense of the pregnancy chapter. The JBDS-IP 12 inpatient guideline (Joint British Diabetes Societies for Inpatient Care) anchors the management of glycaemic control in pregnant women with diabetes on obstetric wards and delivery units; the protocol the trust uses is shaped by JBDS-IP 12 alongside local custom.

The immediate postpartum insulin drop is sharp. The placenta-driven insulin resistance of the third trimester ends abruptly when the placenta is delivered; the reader’s insulin requirement falls sharply in the first 24 hours after the birth, and the hypoglycaemia risk rises in parallel. The settings need a fresh review with the diabetes team in the first 24 to 72 hours after delivery (NICE NG3, ADA 2026 §15, JBDS-IP 12). The household carries the noticing alongside the team in this window; the partner reading the CGM alerts on a second phone, the midwife reading the trace on the postnatal ward, the diabetes team on call for the settings change.

Breastfeeding and the first months at home

Breastfeeding adds a real piece of diabetes work in the first months at home. The literature (ADA 2026 §15; lighter cross-reference to Quirós 2026 and Stathi 2026 on postnatal follow-up in T1D) consistently flags that breastfeeding adds carbohydrate needs and can lower insulin sensitivity, particularly in the first weeks. Planning meals around feeds, and naming the night-feed pattern at the next diabetes review, reduces overnight hypoglycaemia risk in the months after the birth.

The first months at home are also a settings-review period. The settings the team set immediately postpartum are rarely the settings the reader will sit on at six months; the trajectory of the insulin requirement across the first months is a conversation the diabetes team will revisit at each routine review. The cadence of the diabetes appointments often steps up for the first months and then settles back into the pre-pregnancy pattern as the new rhythm beds in.

Questions to bring to the joint antenatal-diabetes clinic

The joint antenatal-diabetes clinic visits are the conversation that ties the trimesters together. The questions that move the visits forward most reliably are the specific ones, drawn from the reader’s own CGM data, rather than the broad ones drawn from the literature. We bring them as a household where the partner is part of the conversation; the reader owns the appointment, the partner owns the supporting work.

Bring the current target range and any drift in the trace across the last fortnight. Bring the AHCL pregnancy-specific settings question if the reader is on AHCL; whether the current band is the band the team wants for this trimester. Bring the intrapartum plan question as the third trimester progresses; what the protocol will look like on the day, where the responsibility sits, who is in the room. Bring the postpartum settings review question; what the immediate settings change will look like, who will be on call. Bring the breastfeeding planning question; the night-feed pattern, the meal planning. Bring the follow-up cadence question for the first months at home.